Italia markets open in 8 hours 6 minutes

Aptose Biosciences Inc. (0UI8.L)

LSE - LSE Prezzo differito. Valuta in CAD.
Aggiungi a watchlist
3,0500+3,0500 (-58,89%)
Alla chiusura: 02:52PM GMT
Schermo intero
Chiusura precedente7,4200
Aperto0,0000
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume0
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)1,56
Rapporto PE (ttm)N/D
EPS (ttm)-0,8750
Prossima data utili20 mar 2023 - 24 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia

    • AML Patients Receive Tuspetinib Monotherapy to Kick Off APTIVATE Phase 1/2 Trial• New Response Emerges with 40 mg Tuspetinib in FLT3 Wildtype AML Patient• Aptose Elucidates Rationale for Tuspetinib’s Superior Safety Profile SAN DIEGO and TORONTO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnost

  • GlobeNewswire

    Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference

    SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate at the upcoming Biotech Showcase™ 2023 Conference on Tuesday, January 10th, 2023, at 10:00 a.m. PST in San Francisco, CA. Conference Presentation D

  • GlobeNewswire

    Aptose Biosciences Establishes New At-The-Market Facility

    SAN DIEGO and TORONTO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced it has entered into an equity distribution agreement (the “Equity Distribution Agreement”) with JonesTrading Institutional Services LLC, as agent (the “Agent”). Under the terms of the Equity Distribution Agreement,